Budget Amount *help |
¥42,770,000 (Direct Cost: ¥32,900,000、Indirect Cost: ¥9,870,000)
Fiscal Year 2019: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2018: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2017: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
|
Outline of Final Research Achievements |
In this study, we have done several basic studies about adenoviruses (Ad) in terms of viral replication, microRNA, immune responses, etc. And then, through such basic studies, we tried to develop several types of novel recombinant Ad vectors for gene therapy, vaccine, viral therapy, etc. We also developed novel Ad vectors having gene editing functions.
|